The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
A federal judge in California has blocked President Donald Trump from building sections of his long-sought border wall with money secured under his declaration of a national...Politicsread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
The race is underway to find a vaccine that can control African swine fever, a highly contagious and deadly viral infection ravaging China's hog population. There is currently...Agricultureread more
Apple bought Tueo Health, which was developing tech to help parents monitor asthma symptoms in children, using a mobile app and commercial breathing sensors.Technologyread more
Allergan shares rose Tuesday after billionaire hedge fund manager David Tepper increased his pressure on the drugmaker, calling for the company to jump-start the business with new strategies and recommending again that it separate the CEO and chairman roles.
The stock rose about 1 percent Tuesday after the Appaloosa Management president lambasted Allergan's executives, characterizing recent decision-making at $47 billion Allergan as "self-inflicted wounds" and marred by "ill-considered initiatives."
"In the wake of last Tuesday's earnings call (and market reaction) it should by now be readily apparent to all interested and responsible parties that Allergan requires a fresh approach to its business strategy and an unbiased review of its capabilities, opportunities, and way forward," Tepper wrote in Appaloosa's letter. "Of course, fully arresting AGN's decline will require rigorous follow-through and likely more radical remediation measures."
Appaloosa first asked Allergan's board to separate the roles of chairman and CEO in a letter dated April 23, 2018. Despite two subsequent letters advocating the change, the Allergan directors have "ignored" similar proposals in the past, Tepper said.
Allergan offered the following statement to CNBC:
"Allergan's Board of Directors has received Appaloosa's proposal and is committed to continuing to engage with them, as we do any shareholder who has input and constructive ideas. The Board of Directors is committed to strong governance practices and independent board leadership. The company has been executing its strategy to drive growth and value for shareholders as it transforms into a global biopharmaceutical leader. Allergan has a strong long-term outlook across its four key therapeutics areas and a highly promising R&D pipeline."
The company reported a $4.3 billion loss in the fourth quarter as it posted about $5.4 billion in pretax impairment charges. It reported last week a loss of $12.83 a share, an about-face compared with profits of $8.88 a share from a year ago. Analysts polled by Refinitiv were expecting a loss of 44 cents a share.
Appaloosa Management has approximately $14 billion of assets under management. Tepper also owns the National Football League team Carolina Panthers.